Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, offers next-generation technological solutions for the neurology market. The company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), allow quick and reliable EEG testing in minutes and by any health care worker, not only specialized neurological technicians, bringing brain diagnostics to settings in which neurological testing was previously impossible or difficult. “As we learn more about COVID-19, it is becoming increasingly clear that neurological care in the post-COVID world will be crucial,” reads a recent article. This revelation comes amid findings by scientists who are starting to collect more and more data. Research has demonstrated that COVID patients suffer from neurological symptoms. “However, the new comprehensive cross-country study recently published in the Journal of Neurology, Neurosurgery and Psychiatry reveals that neurological symptoms may actually be the norm rather than an exception.” As a result, Brain Scientific “could be the one offering a solution to the rising challenge global health systems face in the post-COVID world.”
To view the full article, visit https://ibn.fm/TeDa6
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork